Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand name Ozempic), chronic weight management (Wegovy), and cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight
At this point, we suggest to better investigate the effect of different dosages by a randomized, double-blind placebo-controlled, longitudinal prospective trial, with three arms (placebo, ALCAR 3 g/day, ALCAR 1.5 g/day) and long-term follow up (12 months)
However, noticeable weight loss typically takes a bit longer, often occurring within 12 to 16 weeks of consistent use
Its also essential that you understand that your semaglutide results will depend on your commitment to a healthier diet and active lifestyle
Products like simethicone or activated charcoal may provide short-term relief, especially during the adjustment phase
Reduced appetite suppression is often the first functional sign of potency loss